N05AD01 - Haloperidol |
Propably not porphyrinogenic |
PNP |
Rationale
No data pointing to CYP-induction. Repeatedly used in acute porphyria without ill effects. Several references state non-porphyrinogenicity.
Chemical description
(To be edited, initial data ST OCT 04) Butyrphenone low-dose neuroleptic used in psychotic conditions (e.g.in paranoia), also in childhood. Used in confusion states in elderly and against vomiting, e.g. in radiation sickness. Extensively metabolized, CYPs probably involved. No data pointing to CYP-inducing properties. Australian list: safe (conflicting evidence) EPI-list: safe South African list: use French list: use Martindale: Haloperidol is considered to be safe in patients with porphyria although there is conflicting experimental evidence of porphyrinogenicity.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
© NAPOS 2024